RIBONEXUS
Ribonexus is a biotech specialized in the development of new therapies to combat cancer disease.
RIBONEXUS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2021-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Status:
Active
Total Funding:
6 M EUR
Current Employees Featured
Founder
Investors List
Bpifrance
Bpifrance investment in Debt Financing - Ribonexus
Bpifrance
Bpifrance investment in Grant - Ribonexus
Pierre Fabre
Pierre Fabre investment in Seed Round - Ribonexus
Crédit Mutuel Innovation
Crédit Mutuel Innovation investment in Seed Round - Ribonexus
AdBio partners
AdBio partners investment in Seed Round - Ribonexus
More informations about "Ribonexus"
Ribonexus - Crunchbase Company Profile & Funding
Ribonexus is a biotech specializing in the development of new therapies to combat cancer disease. Ribonexus, whose research and development …See details»
Ribonexus 2025 Company Profile: Valuation, Funding & Investors
Ribonexus General Information Description. Operator of a biotechnology startup intended to develop therapies that can overcome resistance to current targeted therapies in cancer …See details»
Ribonexus - Medtech Alert
Apr 12, 2022 Ribonexus (previously Aglaia Therapeutics) is a biotechnology start-up developing promising new oncology therapies. The company aims to deliver best- and first- in class drugs that restore sensitivity to current targeted …See details»
Restoring sensitivity to targeted therapies
Feb 23, 2025 Originally named Aglaia Therapeutics (after the plant family), Ribonexus was founded in 2021 with 4 million euros, receiving a further 2 million euros in April 2022.See details»
Aglaia Therapeutics becomes Ribonexus and signs …
Nov 18, 2021 Villejuif and Castres, France, November 18th, 2021 – Ribonexus (previously Aglaia Therapeutics), a biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in …See details»
Ribonexus appoints Dr. David Howat as Chief Development Officer
President of Ribonexus. “With David’s development leadership and regulatory knowledge, the team will be able to accelerate our preclinical programs and get closer to creating a treatment …See details»
Ribonexus appoints Steven Powell as CEO | Andrew …
Dec 14, 2022 Ribonexus has also established strong relationships with French research institutes such as Institut Gustave Roussy and Institut Curie. Based in Villejuif, near Paris, France, Ribonexus was co-founded in 2021 by Adbio …See details»
Ribonexus - Funding, Financials, Valuation & Investors - Crunchbase
Ribonexus is a biotech specializing in the development of new therapies to combat cancer disease. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Ribonexus | Crédit Mutuel Innovation
Ribonexus (former Aglaiä Therapeutics) is a biotechnology startup developing promising new oncology therapies. The company aims at delivering best- and first- in class drugs that restore …See details»
RIBONEXUS | Conectus
Ribonexus is a biotechnology company developing promising new therapies in oncology. Ribonexus' goal is to provide best-in-class or first-in-class drugs that reactivate the response …See details»
Ribonexus | Crédit Mutuel Equity
Apr 30, 2022 “Ribonexus is relying on an expert team to tackle this issue, with the reassuring alliance of an industrial company and top-tier scientists, which gives us a reason to hope for …See details»
Ribonexus signs license deal with Pierre Fabre in oncology
Nov 18, 2021 Scientific co-founders of Ribonexus, Prof Caroline Robert, head of the Dermatology Unit at Gustave Roussy Cancer Campus and Dr Stéphan Vagner, research …See details»
Ribonexus: Overcoming resistance to cancer treatments
Apr 28, 2022 Ribonexus aims to develop new treatments that can fight targeted therapy resistance in patients with cancer. Testing new molecules. In order to do this, the Ribonexus …See details»
French Bank supports key drug development under Government …
French biotechnology start-up Ribonexus, focused on new therapies that can overcome resistance built up against some targeted treatments for cancer patients, has received €2 …See details»
Ribonexus (Former Aglaia Therapeutics) - DevelopmentAid
Ribonexus (Former Aglaia Therapeutics) — Consulting Organization from France, has experience with Horizon Europe (2021 - 2027), it`s involved in Health, Laboratory & Measurement sectorsSee details»
Aglaia Therapeutics becomes Ribonexus and signs exclusive …
Nov 18, 2021 Villejuif and Castres, France, November 18, 2021 – Ribonexus (previously Aglaia Therapeutics), a biotechnology startup developing promising new therapies that can overcome …See details»
Ribonexus receives €2M in deep tech financing from Bpifrance
Apr 12, 2022 Funds will allow Ribonexus to select best drug candidate to enter preclinical development for melanoma treatment Villejuif, France, April 12, 2022 – Ribonexus, a …See details»
New chief executive seeks more financing for Ribonexus
Dec 14, 2022 French drug resistance specialist Ribonexus has appointed Steven Powell as chief executive, as the company prepares to seek more financing for its small molecul. Wednesday …See details»
Ribonexus | Crédit Mutuel Innovation
Apr 30, 2022 “Ribonexus is relying on an expert team to tackle this issue, with the reassuring alliance of an industrial company and top-tier scientists, which gives us a reason to hope for …See details»
Ribonexus - Contacts, Employees, Board Members, Advisors
Ribonexus is a biotech specializing in the development of new therapies to combat cancer disease. New. Resources. Advanced Search ... Experience the new Crunchbase, powered by …See details»